Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China

Abstract Objectives To explore the drug susceptibility of levofloxacin (LFX), moxifloxacin (MFX), bedaquiline (BDQ), linezolid (LZD), clofazimine (CFZ) and delamanid (DLM) against multidrug resistant tuberculosis (MDR-TB) isolates from drug resistance survey of southwest China, and to illustrate the...

Full description

Bibliographic Details
Main Authors: Huiwen Zheng, Wencong He, Weiwei Jiao, Hui Xia, Lin Sun, Shengfen Wang, Jing Xiao, Xichao Ou, Yanlin Zhao, Adong Shen
Format: Article
Language:English
Published: BMC 2021-04-01
Series:BMC Infectious Diseases
Subjects:
Online Access:https://doi.org/10.1186/s12879-021-06024-8
id doaj-d0ad21e9d229484293b39955f51e823e
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Huiwen Zheng
Wencong He
Weiwei Jiao
Hui Xia
Lin Sun
Shengfen Wang
Jing Xiao
Xichao Ou
Yanlin Zhao
Adong Shen
spellingShingle Huiwen Zheng
Wencong He
Weiwei Jiao
Hui Xia
Lin Sun
Shengfen Wang
Jing Xiao
Xichao Ou
Yanlin Zhao
Adong Shen
Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
BMC Infectious Diseases
Mycobacterium tuberculosis
Drug resistance
Mutation
author_facet Huiwen Zheng
Wencong He
Weiwei Jiao
Hui Xia
Lin Sun
Shengfen Wang
Jing Xiao
Xichao Ou
Yanlin Zhao
Adong Shen
author_sort Huiwen Zheng
title Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
title_short Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
title_full Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
title_fullStr Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
title_full_unstemmed Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
title_sort molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of china
publisher BMC
series BMC Infectious Diseases
issn 1471-2334
publishDate 2021-04-01
description Abstract Objectives To explore the drug susceptibility of levofloxacin (LFX), moxifloxacin (MFX), bedaquiline (BDQ), linezolid (LZD), clofazimine (CFZ) and delamanid (DLM) against multidrug resistant tuberculosis (MDR-TB) isolates from drug resistance survey of southwest China, and to illustrate the genetic characteristics of MDR-TB isolates with acquired drug resistance. Methods A total of 339 strains were collected from smear-positive TB patients in the drug resistance survey of southwest China between January 2014 and December 2016. The MICs for the above mentioned drugs were determined for MDR-TB by conventional drug susceptibility testing. Genes related to drug resistance were amplified with their corresponding pairs of primers. Results MDR was observed in 88 (26.0%; 88/339) isolates. LFX had the highest resistance rate (50.0%; 44/88), followed by MFX (38.6%; 34/88). The resistance rate to LZD, CFZ, and DLM was 4.5% (4/88), 3.4% (3/88), and 4.5% (4/88), respectively, and the lowest resistance rate was observed in BDQ (2.3%; 2/88). Of the 45 isolates resistant to LFX and MFX, the most prevalent resistance mutation was found in gyrA with the substitution of codon 94 (34/45, 75.6%). Two strains with CFZ - BDQ cross resistance had a mutation in the Rv0678 gene. Of the four LZD resistant isolates, two carried mutations in rplC gene. For the four isolates resistant to DLM, one isolate had mutations in codon 318 of fbiC gene, and two isolates were with mutations in codon 81 of ddn gene. Conclusion This study provided evidence of the usefulness of new anti-TB drugs in the treatment of MDR-TB in China.
topic Mycobacterium tuberculosis
Drug resistance
Mutation
url https://doi.org/10.1186/s12879-021-06024-8
work_keys_str_mv AT huiwenzheng molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina
AT wenconghe molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina
AT weiweijiao molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina
AT huixia molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina
AT linsun molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina
AT shengfenwang molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina
AT jingxiao molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina
AT xichaoou molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina
AT yanlinzhao molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina
AT adongshen molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina
_version_ 1721531425826537472
spelling doaj-d0ad21e9d229484293b39955f51e823e2021-04-11T11:08:30ZengBMCBMC Infectious Diseases1471-23342021-04-012111610.1186/s12879-021-06024-8Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of ChinaHuiwen Zheng0Wencong He1Weiwei Jiao2Hui Xia3Lin Sun4Shengfen Wang5Jing Xiao6Xichao Ou7Yanlin Zhao8Adong Shen9Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthNational Tuberculosis Reference Laboratory, Chinese Center for Disease Control and PreventionBeijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthNational Tuberculosis Reference Laboratory, Chinese Center for Disease Control and PreventionBeijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthNational Tuberculosis Reference Laboratory, Chinese Center for Disease Control and PreventionBeijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthNational Tuberculosis Reference Laboratory, Chinese Center for Disease Control and PreventionNational Tuberculosis Reference Laboratory, Chinese Center for Disease Control and PreventionBeijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthAbstract Objectives To explore the drug susceptibility of levofloxacin (LFX), moxifloxacin (MFX), bedaquiline (BDQ), linezolid (LZD), clofazimine (CFZ) and delamanid (DLM) against multidrug resistant tuberculosis (MDR-TB) isolates from drug resistance survey of southwest China, and to illustrate the genetic characteristics of MDR-TB isolates with acquired drug resistance. Methods A total of 339 strains were collected from smear-positive TB patients in the drug resistance survey of southwest China between January 2014 and December 2016. The MICs for the above mentioned drugs were determined for MDR-TB by conventional drug susceptibility testing. Genes related to drug resistance were amplified with their corresponding pairs of primers. Results MDR was observed in 88 (26.0%; 88/339) isolates. LFX had the highest resistance rate (50.0%; 44/88), followed by MFX (38.6%; 34/88). The resistance rate to LZD, CFZ, and DLM was 4.5% (4/88), 3.4% (3/88), and 4.5% (4/88), respectively, and the lowest resistance rate was observed in BDQ (2.3%; 2/88). Of the 45 isolates resistant to LFX and MFX, the most prevalent resistance mutation was found in gyrA with the substitution of codon 94 (34/45, 75.6%). Two strains with CFZ - BDQ cross resistance had a mutation in the Rv0678 gene. Of the four LZD resistant isolates, two carried mutations in rplC gene. For the four isolates resistant to DLM, one isolate had mutations in codon 318 of fbiC gene, and two isolates were with mutations in codon 81 of ddn gene. Conclusion This study provided evidence of the usefulness of new anti-TB drugs in the treatment of MDR-TB in China.https://doi.org/10.1186/s12879-021-06024-8Mycobacterium tuberculosisDrug resistanceMutation